Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 3:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 2,344 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Pharmacokinetics and Pharmacodynamics Clear all

Conditions: Thrombosis
Interventions: BMS-962212, Aspirin, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 691 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 3
States / cities: Cypress, California • Glendale, California • Baltimore, Maryland

Conditions: Ovarian Neoplasms
Interventions: 9-aminocamptothecin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Alport Syndrome
Interventions: RG012; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 7
States / cities: La Mesa, California • Los Angeles, California • Riverside, California + 4 more

Conditions: Healthy
Interventions: MT1002 for injection; Drug
Lead sponsor: Shaanxi Micot Pharmaceutical Technology Co., Ltd.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: IPF
Interventions: HNC1058 Capsules; Drug
Lead sponsor: Guangzhou Henovcom Bioscience Co. Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Breakthrough Pain
Interventions: Inhaled Placebo, Inhaled Fentanyl 25 mcg, Intravenous Fentanyl 25 mcg, Inhaled Fentanyl 25 mcg x 2, Inhaled Fentanyl 25 mcg x 4, Inhaled Fentanyl 25 mcg x 6, Inhaled Fentanyl 25 mcg x 12; Drug
Lead sponsor: Alexza Pharmaceuticals, Inc.; Other
Eligibility: 18 Years to 55 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Obesity and Obesity-related Medical Conditions
Interventions: MET233 and MET097, Placebo, MET097; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 381 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Cypress, California

Conditions: Carcinoma, Midline
Interventions: GSK525762; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 16 Years and older
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 5
States / cities: Baltimore, Maryland • Boston, Massachusetts • Philadelphia, Pennsylvania + 2 more

Conditions: Asthma
Interventions: Fluticasone Furoate, Fluticasone Furoate/Vilanterol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 5 Years to 11 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Huntington Beach, California

Conditions: Advanced Solid Tumors
Interventions: CB-5083; Drug
Lead sponsor: Cleave Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 6
States / cities: Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 3 more

Conditions: Preterm Birth, Preeclampsia
Interventions: Daily aspirin (ASA), Split dose aspirin (ASA); Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 16 Years to 55 Years · Female only
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy Subjects
Interventions: CKD-508 Tablet, Placebo Tablet; Drug
Lead sponsor: Chong Kun Dang Pharmaceutical; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Glendale, California

Conditions: Pain, Tolerance, Oral vs Vaporized THC, Abuse Liability
Interventions: Dronabinol 5 MG, Dronabinol 10 MG, 2mg Purified THC in an ethanolic solution, 4mg Purified THC in an ethanolic solution, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 65 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Friedreich Ataxia
Interventions: Omaveloxolone; Drug
Lead sponsor: Biogen; Industry
Eligibility: 2 Years to 15 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Type2 Diabetes Mellitus
Interventions: Bexagliflozin; Drug
Lead sponsor: Theracos; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 2
States / cities: Boston, Massachusetts • Saint Paul, Minnesota

Conditions: Obesity, Overweight, Healthy
Interventions: PF-04620110, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Moderate-to-severe Atopic Dermatitis
Interventions: CBP-201, placebo; Drug
Lead sponsor: Connect Biopharm LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 38
States / cities: Glendale, Arizona • Phoenix, Arizona • Tempe, Arizona + 32 more

Conditions: FXI
Interventions: FXI-GalNAc-siRNA, Placebo; Drug · Other
Lead sponsor: Sirnaomics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Creve Coeur, Missouri

Conditions: Non-diabetic Overweight or Obese
Interventions: Experimental: 10 mg BGM0504 10 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week., Experimental: 15 mg BGM0504 15 mg BGM0504 administered SC once a week., Placebo Comparator: Placebo Placebo administered subcutaneously (SC) once a week.; Drug
Lead sponsor: BrightGene Bio-Medical Technology Co., Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: LY3502970, Placebo, Atorvastatin, Simvastatin, Midazolam; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 133 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Non-Small-Cell Lung Cancer
Interventions: XL999; Drug
Lead sponsor: Symphony Evolution, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 5
States / cities: Los Angeles, California • Atlanta, Georgia • Detroit, Michigan + 2 more

Conditions: Advanced Solid Tumor
Interventions: SKL27969; Drug
Lead sponsor: SK Life Science, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 4
States / cities: Duarte, California • Grand Rapids, Michigan • Huntersville, North Carolina + 1 more

Conditions: Healthy Adults
Interventions: MIB-725; Drug
Lead sponsor: Metro International Biotech, LLC; Industry
Eligibility: 19 Years to 60 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Coronavirus Disease 2019 (COVID-19)
Interventions: AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061]); Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years and older
Enrollment: 251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 16
States / cities: Birmingham, Alabama • Modesto, California • Westminster, California + 13 more

Search by objective public record fields.

A Short and Long Intravenous Infusion Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-962212 in Healthy Subjects

A Phase II Trial of 72-Hour Continuous IV Infusion of 9-Aminocamptothecin With G-CSF Support in Patients With Advanced Ovarian Cancer Previously Treated With Paclitaxel and Cisplatin

A Study of RG-012 in Subjects With Alport Syndrome

Single Ascending Dose Trial to Evaluate the Safety, Tolerability, PK, and PD of MT1002 for Injection

A Study to Evaluate the Safety, Tolerability, PK and PD of HNC1058

Staccato Fentanyl Single and Multidose PK

A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes

A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers

Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD Study

A Phase 1 Study Evaluating CB-5083 in Subjects With Advanced Solid Tumors

Daily Aspirin vs Split Dosing in High-risk Pregnancies (DASH)

A Study to Investigate the Safety, Tolerability, PK, and PD of CKD-508 in Healthy Participants

PK/PD of Oral and Vaporized Delta-9-Tetrahydrocannabinol (THC) in Older Adults

A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old

Safety and Efficacy of Bexagliflozin in Subjects With Moderate Hepatic Impairment

A Multiple Dose Study Of PF-04620110 In Overweight And Obese, Otherwise Healthy Volunteers

A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis

Single Ascending Dose of FXI-GalNAc-siRNA in Healthy Subjects

Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Injection in Non-diabetic Overweight or Obese Adult Subjects

A Study of LY3502970 in Healthy Participants

Safety Study of XL999 in Adults With Non-Small-Cell Lung Cancer

Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients

Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults

A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, for Pre-exposure Prophylaxis of COVID-19